Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland · Delayed Price · Currency is CHF 14.16
-0.28 (-1.94%)
Jul 31, 2026, 5:30 PM CET
SWX:SANN Ratios and Metrics
Market cap in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 212 | 169 | 177 | 111 | 91 | 66 | |
Market Cap Growth | 8.39% | -4.49% | 59.19% | 22.09% | 37.85% | 32.39% |
Enterprise Value | 238.58 | 235.2 | 209.56 | 102.18 | 134 | 87.72 |
Last Close Price | 14.16 | 12.60 | 13.82 | 9.81 | 13.80 | 13.30 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 1.96 | - | - |
Forward PE | - | 1.62 | 1.62 | 1.62 | 105.14 | 105.14 |
PS Ratio | 2.75 | 2.19 | 4.52 | 1.07 | 12.17 | -41.35 |
PB Ratio | -17.95 | -14.28 | 6.38 | 1.85 | -2.08 | 49.66 |
P/FCF Ratio | - | - | - | 2.35 | - | - |
P/OCF Ratio | - | - | - | 2.35 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.09 | 3.05 | 5.36 | 0.99 | 17.93 | -55.00 |
EV/EBITDA Ratio | - | - | - | 1.42 | - | - |
EV/EBIT Ratio | - | - | - | 1.48 | - | - |
EV/FCF Ratio | - | - | - | 2.17 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | -6.27 | -6.27 | 2.41 | 0.00 | -0.50 | 20.33 |
Debt / EBITDA Ratio | - | - | - | 0.30 | - | - |
Debt / FCF Ratio | - | - | - | 0.46 | - | - |
Net Debt / Equity Ratio | -5.62 | -5.62 | 1.19 | -0.15 | -0.99 | 16.39 |
Net Debt / EBITDA Ratio | -2.08 | -2.08 | -1.20 | -0.12 | -1.02 | -0.41 |
Net Debt / FCF Ratio | -1.91 | -1.91 | -0.92 | -0.19 | -1.44 | -0.58 |
Asset Turnover | 0.51 | 0.51 | 0.30 | 1.19 | 0.10 | -0.02 |
Inventory Turnover | 2.93 | 2.93 | 1.61 | 3.37 | 13.40 | 8.29 |
Quick Ratio | 0.78 | 0.78 | 1.19 | 0.71 | 0.05 | 0.71 |
Current Ratio | 1.29 | 1.29 | 1.64 | 0.76 | 0.06 | 0.75 |
Return on Equity (ROE) | -620.02% | -620.02% | -95.79% | 673.95% | 335.60% | 2209.55% |
Return on Assets (ROA) | -25.12% | -25.12% | -25.45% | 79.37% | -67.57% | -64.21% |
Return on Invested Capital (ROIC) | -43.94% | -51.55% | -59.74% | 210.28% | -279.70% | -139.59% |
Return on Capital Employed (ROCE) | -39.13% | -39.13% | -38.91% | 176.19% | -143.09% | -96.46% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | - | - | - | 51.07% | - | - |
FCF Yield | - | - | - | 42.50% | - | - |
Buyback Yield / Dilution | -14.29% | -14.29% | -4.24% | -79.29% | -78.31% | -156.61% |
Total Shareholder Return | -14.29% | -14.29% | -4.24% | -79.29% | -78.31% | -156.61% |